Media stories about Revance Therapeutics (NASDAQ:RVNC) have trended somewhat positive on Friday, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Revance Therapeutics earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 47.0623897267302 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Revance late-stage study of RT002 in cervical dystonia underway (seekingalpha.com)
- Revance Doses First Patient in ASPEN Phase 3 Clinical Program of RT002 Injectable for the Treatment of Cervical Dystonia (finance.yahoo.com)
- Brokerages Expect Revance Therapeutics Inc (RVNC) to Announce -$0.92 Earnings Per Share (americanbankingnews.com)
- Comparing Catalyst Biosciences (CBIO) & Revance Therapeutics (RVNC) (americanbankingnews.com)
- 200 days simple moving average (SMA200) Factor Analysis My Size, Inc. (NASDAQ:MYSZ), TimkenSteel Corporation … (stocksnewspoint.com)
Several analysts recently issued reports on the company. BidaskClub raised Revance Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, June 13th. Zacks Investment Research downgraded Revance Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, May 15th. Cantor Fitzgerald set a $50.00 price target on Revance Therapeutics and gave the stock a “buy” rating in a report on Tuesday, May 8th. Mizuho cut their price target on Revance Therapeutics from $54.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, April 20th. Finally, Piper Jaffray Companies set a $48.00 price target on Revance Therapeutics and gave the stock a “buy” rating in a report on Thursday, March 1st. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $45.91.
Revance Therapeutics (NASDAQ:RVNC) last announced its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.26). The business had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.15 million. Revance Therapeutics had a negative net margin of 33,807.37% and a negative return on equity of 63.68%. equities research analysts predict that Revance Therapeutics will post -3.87 earnings per share for the current year.
In other Revance Therapeutics news, CFO Lauren P. Silvernail sold 2,874 shares of Revance Therapeutics stock in a transaction on Tuesday, May 22nd. The stock was sold at an average price of $30.25, for a total transaction of $86,938.50. Following the sale, the chief financial officer now owns 65,497 shares of the company’s stock, valued at approximately $1,981,284.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 18.86% of the stock is owned by insiders.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.